Gan & Lee Insulin Glargine Injection

BIOLOGICAL3 trials

Sponsors

Gan and Lee Pharmaceuticals, USA

Conditions

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Phase 1

PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients

CompletedNCT04236895

Gan and Lee Pharmaceuticals, USADiabetes Mellitus, Type 1

Start: 2018-07-10End: 2018-11-28Updated: 2020-01-22

Phase 3

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

CompletedNCT03371082

Gan and Lee Pharmaceuticals, USADiabetes Mellitus, Type 1

Start: 2017-10-31End: 2019-08-19Updated: 2024-05-14

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

CompletedNCT03371108

Gan and Lee Pharmaceuticals, USADiabetes Mellitus, Type 2

Start: 2017-10-31End: 2019-04-17Updated: 2022-04-01

Related Papers

740-P: Proposed Biosimilar Gan & Lee Insulin Glargine (GL-GLA) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) to U.S.- and EU-Licensed Insulin Glargine (IG)

Diabetes2021-06-01